Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use

Cancer

Volumn 120, Issue 14, 2014, Pages 2150-2157

  Giannini, Edoardo G ^a   Sammito, Giorgio ^a   Farinati, Fabio ^b   Ciccarese, Francesca ^c   Pecorelli, Anna ^d   Rapaccini, Gian Lodovico ^e   Di Marco, Mariella ^f   Caturelli, Eugenio ^g   Zoli, Marco ^d   Borzio, Franco ^h   Cabibbo, Giuseppe ⁱ   Felder, Martina ^j   Gasbarrini, Antonio ^k   Sacco, Rodolfo ^l   Foschi, Francesco Giuseppe ^m   Missale, Gabriele ⁿ   Morisco, Filomena ^o   Svegliati Baroni, Gianluca ^p   Virdone, Roberto ^q   Trevisani, Franco ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Division of Vascular Surgery   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f Division of Medicine Bolognini Teaching Hospital   (Italy)

^g BELCOLLE HOSPITAL   (Italy)

^h FATEBENEFRATELLI HOSPITAL   (Italy)

ⁱ UNIVERSITY OF PALERMO   (Italy)

^j CENTRAL HOSPITAL OF BOLZANO   (Italy)

^k FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^l UNIVERSITY HOSPITAL OF PISA   (Italy)

^m Department of Internal Medicine Faenza Hospital for the Infirm   (Italy)

ⁿ UNIVERSITY HOSPITAL OF PARMA   (Italy)

^o UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^p UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^q United Hospitals Villa Sofia Cervello   (Italy)

more..

Author keywords

alanine aminotransferase; cirrhosis; female; oncology

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; SERUM ALBUMIN; TUMOR MARKER;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CHILD PUGH SCORE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; SEX DIFFERENCE; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR VOLUME; ADULT; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPLICATION; ENZYMOLOGY; ITALY; LIVER FUNCTION TEST; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; VIROLOGY;

ADULT; AGED; ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS C; HUMANS; ITALY; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SERUM ALBUMIN; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903775457     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28706     Document Type: Article

References (44)

1. Forner A, Llovet JM, Bruix J,. Hepatocellular carcinoma. Lancet. 2012; 379: 1245-1255.
2. Trevisani F, Cantarini MC, Wands JR, Bernardi M,. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis. 2008; 29: 1299-1305.
3. El-Serag HB,. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142: 1264-1273.
4. Zhang BH, Yang BH, Tang ZY,. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 127: 35-50.
5. Trevisani F, Santi V, Gramenzi A, et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol. 2007; 102: 2448-2457. (Pubitemid 47631760)
6. Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med. 2008; 121: 119-126. (Pubitemid 351199465)
7. Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010; 53: 291-297.
8. Izzo F, Piccirillo M, Albino V, et al. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients. HPB (Oxford). 2013; 15: 985-990.
9. Bruix J, Sherman M,; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-1022.
10. European Association for the Study of the Liver; European Organization for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908-943.
11. Italian Association for the Study of the Liver (AISF); AISF Expert Panel; AISF Coordinating Committee. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis. 2013; 45: 712-723.
12. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS,. Hepatocellular carcinoma serum markers. Semin Oncol. 2012; 39: 410-433.
13. Sherman M,. Current status of alpha-fetoprotein testing. Gastroenterol Hepatol. 2011; 7: 113-114.
14. Sherman M, Bruix J, Porayko M, Tran T,; AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012; 56: 793-796.
15. Bayati N, Silverman AL, Gordon SC,. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol. 1998; 93: 2452-2456. (Pubitemid 29018554)
16. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006; 101: 524-532. (Pubitemid 43340928)
17. Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005; 43: 434-441. (Pubitemid 41111424)
18. Chen TM, Huang PT, Tsai MH, et al. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol. 2007; 22: 669-675.
19. Sterling RK, Wright EC, Morgan TR, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012; 107: 64-74.
20. Sherman M,. α-Fetoprotein: an obituary. J Hepatol. 2001; 34: 603-605.
21. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001; 34: 570-575. (Pubitemid 32328514)
22. Giannini EG, Farinati F, Trevisani F,. Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead. Hepatology. 2011; 54: 376-377.
23. Giannini EG, Erroi V, Trevisani F,. Effectiveness of α-fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead? Expert Rev Gastroenterol Hepatol. 2012; 6: 441-444.
24. El-Serag HB, Kanwal F,. α-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol. 2013; 11: 441-443.
25. Lee E, Edward S, Singal AG, Lavieri MS, Volk M,. Improving screening for hepatocellular carcinoma by incorporating data on levels of α-fetoprotein, over time. Clin Gastroenterol Hepatol. 2013; 11: 437-440.
26. Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012; 143: 986-994.
27. Xu XS, Qu K, Liu C, et al. Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma. World J Gastroenterol. 2012; 18: 7242-7250.
28. Nomura F, Ohnishi K, Tanabe Y,. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: analysis of 606 patients. Cancer. 1989; 64: 1700-1777.
29. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC,. High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and β-catenin mutation. Int J Cancer. 2004; 112: 44-50. (Pubitemid 39249490)
30. Santi V, Buccione D, Di Micoli A, et al. The changing scenario of hepatocellular carcinoma over the last 2 decades in Italy. J Hepatol. 2012; 56: 397-405.
31. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R,. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60: 646-649.
32. Edmondson HA, Steiner PE,. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954; 7: 462-503.
33. Paradis V,. Histopathology of hepatocellular carcinoma. Recent Results Cancer Res. 2013; 190: 21-32.
34. Watanabe A, Shiota T, Hayashi S, Nagashima H,. Serum alphafetoprotein in fulminant hepatitis and hepatic regeneration following partial hepatectomy. Biochem Med. 1984; 32: 132-137. (Pubitemid 14096050)
35. Horn KD, Wax P, Schneider SM, et al. Biomarkers of liver regeneration allow early prediction of hepatic recovery after acute necrosis. Am J Clin Pathol. 1999; 112: 351-357. (Pubitemid 30214774)
36. Asahina Y, Tsuchiya K, Nishimura T, et al. α-Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013; 58: 1253-1262.
37. Oze T, Hiramatsu N, Yakushijin T, et al. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy [published online ahead of print December 7, 2013]. Clin Gastroenterol Hepatol. 2013.
38. Farinati F, Sergio A, Giacomin A, et al. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol. 2009; 21: 1212-1218.
39. Giannini EG, Marabotto E, Savarino V, et al. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol. 2009; 7: 580-585.
40. Torres DM, Harrison SA,. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis. 2012; 32: 30-38.
41. Wong RJ, Cheung R, Ahmed A,. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US [published online ahead of print December 25, 2013]. Hepatology. 2013.
42. Merani S, Majno P, Kneteman NM, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011; 55: 814-819.
43. Lee YK, Kim SU, Kim do Y, et al. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization [serial online]. BMC Cancer. 2013; 13: 5.
44. Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012; 57: 101-107.